1. Home
  2. |Insights
  3. |Crowell & Moring Represents Third Rock Ventures in $108 Million Series C Financing for Terremoto Biosciences

Crowell & Moring Represents Third Rock Ventures in $108 Million Series C Financing for Terremoto Biosciences

Firm News | less than 1 min read | 04.15.26

Boston and San Francisco – April 15, 2026: Crowell & Moring represented investor Third Rock Ventures in the closing of a $108 million Series C financing round for Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines.  

Along with Third Rock, the financing included support from existing investors OrbiMed, Novo Holdings, and Cormorant Asset Management, LP, as well as from new investors RA Capital Management, Deep Track Capital, Osage University Partners (OUP), and BeOne Medicines. Proceeds from the financing will enable Terremoto to advance its selective AKT1 inhibitor programs through Phase 1 clinical development for patients with cancer and rare diseases such as hereditary hemorrhagic telangiectasia. 

The financing transaction was led by partner Kurt Machemer (Boston). 


Insights

Firm News | 1 min read | 11.12.26

Crowell Authors U.S. Chapters for Global Legal Post’s Mining Law Comparative Guide

November 12, 2026: Crowell & Moring’s John J. Koenigsknecht, David S. Stone, Elaine Taussig, Ryan Flynn, and Christian Lichtenberger have authored the U.S. “Market Insights” and U.S. “Country Q&A” chapters of the inaugural edition of the Global Legal Post’s Mining Law Comparative Guide. The guide provides practical insight into the legal and regulatory frameworks governing mining across jurisdictions globally, including North America, South America, Africa, and Asia, and will be distributed on a worldwide basis. ...